FILTER
FILTERED ARTICLE RESULTS
Standing Out in the Biotech Crowd: The VC Investment Climate
February 06, 2019
With biotechs now accounting for 70% of clinical trials in the United States, the VC private investment climate is heating up.
The Indispensable Partner: Contract Services
October 31, 2018
Large Pharma companies often turn to CMOs and CDMOs for specialized expertise, while Biotech startups rely upon their labs and hardware, resulting in a rapidly expanding and increasingly global business.
From Volume to Value: A Shift in Innovation Focus in the U.S.
August 30, 2018
Precision medicine and the understanding that every patient is different are driving drug discovery.
Patient Selection: The Right Drug for the Right Patient
June 06, 2018
By better defining addressable patient populations and more precisely predicting likely individual responses, companies are able to reduce a great deal of risk in their clinical trials.
Infectious Diseases: Addressing Growing Resistance
April 26, 2018
The infectious disease space is one of high unmet need. However, this particular market segment carries an additional challenge: drug resistance.
Finding Funding: The Diversification of the Biotech Financing Landscape
March 27, 2018
The methods of financing biotech R&D are evolving as large pharma companies and governments look to small biotech start-ups to provide the next generation of medicines.
The Winning Formula: Building the Number One Biopharmaceutical Supercluster
February 22, 2018
Massachusetts offers perhaps the most attractive environment for biopharmaceutical research and development in the world, and is fast closing the gap with its rival supercluster in California.
Quality: A Means for Value Creation
June 19, 2017
Firms must shift focus from Quality for Compliance to Quality as a Culture by keeping the end patient in mind.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
